Imatinib is a highlyselective inhibitor of the Abl, BCRABL, PDGFRα/β, and KIT kinases; itis used in BCRABL- positive leukemia and GISTs carrying mutations inKIT and PDGFR. Imatinib is used incombination with other anti-leukemic drugs in AML. This evidence concerns the gene ABL1 and acute myeloid leukemia.